All In Biotech

Drug Trial Radar · NCT07939919

A Study of AK158D1 in Advanced Solid Tumors

A Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AK158D1 in Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

349

Planned (sponsor's estimate)

Start

Nov 16, 2026

Primary completion

Apr 30, 2028

Study completion Apr 30, 2030

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, phase I clinical study aimed at evaluating the safety, tolerability, pharmacokinetics and preliminary antitumor efficacy of AK158D1 in advanced solid tumors.

Conditions

  • Solid Malignant Tumor

Interventions

  • AK158D1Drug

    Subjects will receive AK158D1 via intravenous infusion (IV) in prespecified dose levels.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLTs)Time frame: At the end of Cycle 1 (each cycle is 21 days)
  2. Adverse Events (AEs)Time frame: Up to approximately 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.